XFUSION
18.5.2024 05:38:44 CEST | Business Wire | Press release
xFusion Digital Technologies Co., Ltd. (xFusion) dazzled attendees with its top-of-the-range computing products and solutions at the prestigious ISC High Performance 2024 event, hosted at the Congress Center Hamburg in Germany from May 13th to 15th. During the event, xFusion and fellow participants delved into the realms of AI and high performance computing (HPC) to explore their innovative applications and developmental trends, marking a significant convergence of minds and technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240516487957/en/
(Photo: xFusion)
Tab Tang , President of the Computing and Expansion at xFusion, delivered a keynote titled "Reinvent HPC in the Era of AI" during the Vendor Roadmap session on the 15th. He illuminated the pivotal role of smart computing in propelling industrial progress, highlighting the cooling challenges arising from high power and computing density, along with sustainability concerns. This necessitates clusters that are not only high-speed and low-latency but also highly reliable and stable. He also emphasized the transformative impact of AI on scientific endeavors, affirming xFusion's commitment to overcoming these challenges through pioneering software and hardware solutions. With a unified platform for both HPC and AI, xFusion aims to invigorate academic research and reshape the landscape of AI-driven HPC.
This year's ISC witnessed xFusion's spotlight on cutting-edge technologies like AI and HPC, presenting computing advancements characterized by openness, intelligence, eco-friendliness, and high-density. This compelling showcase drew attendees eager to delve deeper into these innovations.
At the event, xFusion proudly introduced FusionPoD for AI, a revolutionary rack-scale liquid-cooling cabinet poised to redefine computing paradigms. With its open architecture and support for diverse computing capabilities, FusionPoD for AI integrates groundbreaking architectural, software, and algorithmic innovations. It offers a fresh perspective by embracing multiple ecosystems, diversity, and low-carbon solutions to cater to the demanding requirements of AI large models and other HPC scenarios. This remarkable product delivers an unparalleled computing density of 64 GPUs and features a 100% liquid cooling native design with an impressively low pPUE of 1.06. xFusion also introduced the AI Space accelerator to both partners and customers, promising to expedite their AI application development and deployment.
xFusion stole the spotlight at ISC 2024 by showcasing its FusionOne HPC solution tailored for diverse HPC applications in education, scientific research, and manufacturing simulation. This state-of-the-art offering boasts adaptive characteristics, ensuring efficient, secure, reliable, and easily manageable operations. Notably, FusionOne HPC has already made waves with its deployment in the Weiming No. 2 Cluster at Peking University in 2023. This implementation has addressed the diverse needs of various disciplines, facilitating large-scale data processing and scientific computing while simultaneously reducing power consumption and fostering green research initiatives.
Beyond technological excellence, xFusion leads the charge in delivering comprehensive global business support through its dedicated team, bolstering remote O&M, cluster systems, and open architectural frameworks. Collaborating closely with partners, xFusion drives continuous innovation, fostering a thriving and sustainable HPC ecosystem. The current partnership with Bank Neo Commerce (BNC) in Indonesia marks a pivotal step in revolutionizing digital banking services. By offering agile, secure, and scalable digital infrastructure, xFusion empowers BNC to handle increasing transaction volumes and enhance customer interactions, fueling ongoing innovation and development in local digital banking services. FusionOnline, xFusion's remote intelligent O&M platform, is facilitating remote O&M in Europe, streamlining maintenance efforts while ensuring the long-term stability of user services.
Guided by the vision and mission of "Let Computing Serve You Better", xFusion has expanded its reach to over 100 countries and regions, cementing its status as a premier provider of computing infrastructures and services globally.
Looking to the future, xFusion remains optimistic about the potential of HPC to revolutionize industries and drive transformative innovation. In the era of AI, our ongoing contributions to the advancement of HPC underscore our commitment to shaping a brighter, more efficient, and interconnected world powered by our top-notch computing products and solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240516487957/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom